GridAI Technologies Corp.
GRDX
NASDAQ·Healthcare·Biotechnology·Mkt cap $27.2M
$3.44
▼ -6.57%
P/E
—
Mkt Cap
$27.2M
52-Wk Range
$1.87–$6.93
52-Week Range
$1.87 - $6.93
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 9.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Non-systemic delivery technology reducing side effects
- Specialized GI disease focus with targeted expertise
- Diversified pipeline across multiple GI indications
- Clinical-stage assets with patent protection
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Stable outlook
Clinical trial progression and regulatory approvals
Value
Valuation data unavailable
Momentum
Weak
-14.4% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GRDX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 16, 2026
AUG 21, 2026
Reported EPS of -$0.44 vs -$11,340.00 consensus (+100.0% surprise). Revenue of $85.9K vs $85.9K expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+100.0%
Revenue trend · last 8Q
—
—
—
—
—
-62%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$95.8K
$0
$0
$0
$36.3K
$38.2K
$85.9K
Margins · last 8Q
Gross
0.0%
Profit
-257.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GRDX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related